Status:
COMPLETED
A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma
Lead Sponsor:
Sun Pharma Advanced Research Company Limited
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Safety and bioequivalence of SPARC\_147709
Eligibility Criteria
Inclusion
- Availability for the entire study period and willingness to adhere to protocol requirements.
- Diagnosis of multiple myeloma and eligible for receiving Doxorubicin liposome
- 18 years of age or older
- No evidence of underlying disease (except multiple myeloma)
Exclusion
- History or presence of significant allergy or significant history of hypersensitivity or idiosyncratic reactions to doxorubicin hydrochloride
- History of cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic,dermatologic, musculoskeletal, neurological or psychiatric disease.
- History of smoking (≥ 10 cigarettes/day) or consumption of tobacco products (≥ 4 chews/day).
- Positive result to HIV, HCV, RPR and HBsAg.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00863174
Start Date
November 1 2010
End Date
April 1 2011
Last Update
May 3 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.